NCT00112463 · REGISTRY CONDITION SEARCH

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2017-06-14

This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Tumor Response (Complete and Partial)

→

outcome · POSTED

Time to Progression

→

outcome · POSTED

Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3

→

outcome · POSTED

Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed soft tissue sarcoma (STS), including, but not limited to, the following histologies: * Gastrointestinal stromal tumors (GIST) * Refractory to imatinib mesylate * Desmoplastic small round cell tumors * Clear cell sarcoma * Extraskeletal osteosarcoma\* * Extraskeletal Ewing's sarcoma\* * Extraskeletal (myxoid) chondrosarcoma\* * Secondary STS (e.g., radiation-induced STS or neurofibrosarcoma due to neurofibromatosis) allowed * Metastatic or unresectable disease * No standard curative therapy exists * Patients with GIST must have received and progressed on imatinib mesylate * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * No known brain metastases * Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2 * Performance status - Karnofsky 50-100% * More than 3 months * White blood cells (WBC) â¥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) â¤ 2.5 times upper limit of normal (ULN) * Bilirubin normal * Creatinine \< 1.5 times ULN * Creatinine clearance ≥ 60 mL/min * QTc ≤ 480 msec Exclusion Criteria: * No cardiac abnormalities (e.g., congenital long QT syndrome) * No myocardial infarction within the past year * No history of coronary artery disease (e.g., angina Canadian Class II-IV or positive stress imaging study) * No cardiac ischemia (ST depression \>2 mm) by electrocardiogram (ECG) * No New York Heart Association Class II-IV congestive heart failure * Ejection fraction \> 50% by multi gated acquisition scan (MUGA) scan or echocardiogram * No history of sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, or cardiac arrest unless controlled by an automatic implantable cardioverter defibrillator * No hypertrophic or restrictive cardiomyopathy from prior treatment or other causes * No significant left ventricular hypertrophy * No uncontrolled hypertension (i.e., blood pressure ≥ 160/95 mm Hg) * No cardiac arrhythmia requiring anti-arrhythmic medication * Beta blocker or calcium channel blocker allowed * Patients on digitalis that cannot be discontinued not allowed * No Mobitz II second degree block without a pacemaker (first degree or Mobitz I second degree block, bradyarrhythmias, or sick sinus syndrome require Holter monitoring and evaluation by cardiology) * No uncontrolled dysrhythmia * No poorly controlled angina * No other cardiac disease * No history of allergic reaction attributed to compounds of similar chemical or biological composition to FR901228 * No ongoing or active infection * No iatrogenic immune deficiency or immune deficiency secondary to an underlying disorder * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Potassium ≥ 4.0 mmol/L * Magnesium ≥ 2.0 mg/dL * No other uncontrolled illness * No psychiatric illness or social situation that would preclude study compliance * No concurrent anticancer biologic agents * No more than 1 prior chemotherapy regimen for sarcoma * Adjuvant chemotherapy preceding disease relapse is considered 1 prior chemotherapy regimen * Patients with GIST may have received up to 3 prior chemotherapy regimens comprising imatinib mesylate and/or sunitinib malate provided no other chemotherapy agents were used * No prior FR901228 (depsipeptide) * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * No prior cumulative doxorubicin dose \> 500 mg/m\^2 * No other concurrent anticancer chemotherapy * At least 4 weeks since prior radiotherapy * No concurrent anticancer radiotherapy * At least 4 weeks since prior surgery * No prior organ transplantation * Recovered from all prior therapy * No concurrent medications that cause QTc prolongation * No concurrent combination highly active anti-retroviral therapy for HIV-positive patients * No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g., sodium valproate) * No other concurrent investigational agents * No other concurrent anticancer agents
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
intervention Names
Drug: romidepsin
label
Treatment (single-agent depsipeptide)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (single-agent depsipeptide)
description
DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
name
romidepsin
other Names
FK228
FR901228
Istodax
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 40
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Objective tumor response was evaluated using the criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee (JNCI 92(3):205-216,2000). Changes in only the largest diameter (unidimensional measurement) of the target lesions are used. A sum of the longest diameter (LD) for all target lesions was calculated and reported as the baseline sum LD. The baseline sum LD was used as reference by which to characterize the objective tumor response. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum LD; Overall Response (OR) = CR + PR
measure
Objective Tumor Response (Complete and Partial)
time Frame
While on treatment - max of 16 months
description
Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression is the number of months from first treatment until the date of progression.
measure
Time to Progression
time Frame
Until disease progression - max of 48 months
description
The outcome reported here is the number (%) of participants who experienced grade 3 or greater toxicity while on study. A summary of the individual toxicities can be found in the AE/SAE results.
measure
Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3
time Frame
During treatment (max of 16 months) and for 1 month following treatment

secondary Outcomes

description
Months from first treatment until death or the last date of contact
measure
Survival
time Frame
Max of 98 months

Full study description

brief Summary: This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
detailed Description: PRIMARY OBJECTIVES: I. To estimate the response rates of metastatic or unresectable soft tissue sarcomas to single-agent depsipeptide. II. To estimate the time to progression of metastatic or unresectable soft tissue sarcomas to single-agent depsipeptide. III. To evaluate the scope and extent of acute toxicities associated with single-agent depsipeptide when given to patients with soft tissue sarcomas. OUTLINE: This is a multicenter study. Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR. After completion of study treatment, patients are followed up every 2 months.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f4871802946c42ab23f3
requested nct id
NCT00112463
primary nct id
NCT00112463
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Histiocytoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
payload sha256
08e716c8e1e8c8d2b2b0a4ba8c36dd1025091942bb247eb5a9e3cb646c3ab87d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f4871802946c42ab23f3
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00112463
occurrences
context exact
NCT00112463
end
11
exact text
NCT00112463
start
0
offset unit
unicode_code_points
query cond
Histiocytoma
query disease state id
ds-histiocytoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-histiocytoma-000.json
source file sha256
bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
source json pointer
/studies/21/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5296a0969b48a3fad048b00a0737ba1ca3a652aa666fe38a79792a6e4d5c31c3
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Histiocytoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice